Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Art Krieg, Philip Ranker, Richard Ho

Premium

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.

Krieg previously served as CEO of gene-activation firm Rana Therapeutics, which he cofounded in 2011. Before that, he led Pfizer's oligonucleotide therapeutics unit.

He remains a Rana senior advisor and scientific advisory board member.


Troubled RNAi drug firm Marina Biotech disclosed this month the resignations of CFO Philip Ranker and executive VP of research and development Richard Ho.

The departures come after Marina shut down essentially all of its operations in mid-2012 due to lack of funding.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.